Create a narrative

PTC Therapeutics Community

NasdaqGS:PTCT Community

1 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

Create a narrative

PTC Therapeutics

AN

AnalystConsensusTarget

Consensus Narrative from 14 Analysts

2025 Approvals Of Sepiapterin And Vatiquinone Will Meet Unmet Medical Needs

Key Takeaways Multiple anticipated regulatory approvals and successful product launches are expected to significantly boost PTC Therapeutics' revenues. Strong financial collaboration with Novartis positions PTC for substantial earnings growth through milestones, profit sharing, and royalties.

US$64.64

FV

22.9% undervalued

9.40%

Revenue growth p.a.

0

0

0

Updated